Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Long-Term Efficacy and Safety (27 months) of the Biosimilar CT-P10 in Patients with Low Tumor Burden Follicular Lymphoma

Blood (2020) 136 (Supplement 1): 27–28.

https://doi.org/10.1182/blood-2020-135999

Published: 2020

Journal Articles

Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial

Blood (2020) 135 (24): 2137–2145.

https://doi.org/10.1182/blood.2020004856

Published: 2020

Includes: Supplemental data

Journal Articles

Interim Results of Russian Acute Lymphoblastic Leukemia (RALL-2016) Study with Centralized MRD-Monitoring and Randomization for Autologous HSCT with Non-Myeloablative Conditioning in Adult Ph-Negative ALL Patients

Blood (2019) 134 (Supplement_1): 5072.

https://doi.org/10.1182/blood-2019-124701

Published: 2019

Journal Articles

Comparison of Efficacy and Safety of Biosimilar CT-P10 to Rituximab in Patients with Previously Untreated Low Tumor Burden Follicular Lymphoma (LTBFL): A Randomized Phase III Study

Blood (2018) 132 (Supplement 1): 1596.

https://doi.org/10.1182/blood-2018-99-110334

Published: 2018

Journal Articles

Ibrutinib + Obinutuzumab Versus Chlorambucil + Obinutuzumab As First-Line Treatment in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL): Results from Phase 3 iLLUMINATE

Carol Moreno, MD PhD, Richard Greil, MD, Fatih Demirkan, MD, Alessandra Tedeschi, MD, Bertrand Anz, MD, Loree Larratt, MD, Martin Simkovic, MD PhD, Olga Samoilova, MD, Jan Novak, MD PhD, Dina Ben-Yehuda, MD, Vladimir Strugov, MD, Devinder Gill, MD MRCP, FRCPath, John G. Gribben, Emily Hsu, PhD, Cathy Zhou, MS, Fong Clow, ScD, Danelle F. James, MD MAS, Lori Styles, MD, Ian W. Flinn, MD PhD

Blood (2018) 132 (Supplement 1): 691.

https://doi.org/10.1182/blood-2018-99-111370

Published: 2018

Journal Articles

A Global, Randomized, Placebo-Controlled, Phase 3 Study of Ibrutinib Plus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (RCHOP) in Patients with Previously Untreated Non-Germinal Center B-Cell-like (GCB) Diffuse Large B-Cell Lymphoma (DLBCL)

Anas Younes, MD, Laurie H Sehn, MDMPH, Peter Johnson, MD, Pier Luigi Zinzani, MD, Xiaonan Hong, MD, Jun Zhu, Olga Samoilova, MD, Cheolwon Suh, Itaru Matsumura, MD, Andres Lopez-Hernandez, MD, Ulrich Dührsen, Prof, MD PhD, Catherine Thieblemont, MD, Jodi Carey, BSN, RN, Grace Liu, PhD, S. Martin Shreeve, MD PhD, Steven Sun, PhD, Jessica Vermeulen, Louis M. Staudt, MD PhD, Wyndham H. Wilson, MD PhD

Blood (2018) 132 (Supplement 1): 784.

https://doi.org/10.1182/blood-2018-99-112988

Published: 2018

Journal Articles

MRD Status Did Not Correspond to the Relapse Incidence within One Year of Follow-up By Non-Intensive but Non-Interruptive Approach: The First Interim Results of the Russian Prospective Multicenter RALL-2016 Trial for Ph-Negative Adult ALL

Blood (2018) 132 (Supplement 1): 5185.

https://doi.org/10.1182/blood-2018-99-116318

Published: 2018

Journal Articles

Multiple Myeloma in Russia (First Results of the Registration Trial)

Larisa P. Mendeleeva, MD PhD Prof, Maxim V. Solovev, MD, Anna Alexeeva, Ochsana Ochirova, Naida Baygishieva, Imisa Baygishieva, Svetlana Beliaeva, Tatiana V Shelekhova, Varvara Bogova, Elena Borisenkova, Irina Verkhoglyad, Valentine Molostvova, Elena Volodicheva, MD, Elena Voronova, Valery Lapin, Elena Gribanova, Taras Gritsenko, MD, Igor Davydkin, MD PhD, Olga Dianova, Marina Kosinova, Yury Dunaev, MD, Natalia Esefyeva, Ekaterina Zotina, Anna Zarubina, Elena Kirillova, Ekaterina Kalinovskay, Yana Tsinchenko, Kamil D Kaplanov, Mariya Shirokova, Taniana Kaporskaia, Marina Kiseleva, Marina Kozmina, Tatiana Konstantinova, Ekaterina Krupkina, Elena Kuznetcova, Guzaliya Gaynullina, Ekaterina Lisina, Natalia Mashnina, Svetlana Osjnihina, Svetlana Menshikova, Mikhail Mikhalev, Olga Samoilova, Dmitry Morozov, Islam Nakastoev, MD, Maria Novikova, Zhanna Davydova, Elena Patrakova, Natalya Popova, Natalia Rachkova, Irina Rekhtina, Marina Savinova, Tatiana Pospelova, Natalia Skvortsova, Irina Sokolova, Nadezhda Stepanova, Tatyana Sycheva, Elena Tarasenko, Ekaterina Filatova, Valeriy Voytsekhovskiy, Lyudmila Anchukova, Maria Frolova, Anna Khazieva, Elena Martynova, Evgeniy Vasiliev, Tatyana Ksenzova, Ilmil Shackirov, Valery Savchenko, MD PhD academician

Blood (2017) 130 (Supplement 1): 5408.

https://doi.org/10.1182/blood.V130.Suppl_1.5408.5408

Published: 2017

Journal Articles

Systemic Exposure of Rituximab Increased By Ibrutinib: Pharmacokinetic Results from the Helios Trial

Blood (2016) 128 (22): 4403.

https://doi.org/10.1182/blood.V128.22.4403.4403

Published: 2016

Journal Articles

Absence of High-Dose Consolidation Courses and Low Numbers of Allogeneic HSCTs Did Not Affect Overall Optimistic Results in B-Cell Precursor Ph-Negative Adult ALL Patients Treated By Non-Intensive but Non-Interruptive ALL-2009 Protocol: Data of the Russian ALL Study Group

Blood (2015) 126 (23): 2497.

https://doi.org/10.1182/blood.V126.23.2497.2497

Published: 2015

Journal Articles

Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL

Fritz Offner, Olga Samoilova, Evgenii Osmanov, Hyeon-Seok Eom, Max S. Topp, João Raposo, Viacheslav Pavlov, Deborah Ricci, Shalini Chaturvedi, Eugene Zhu, Helgi van de Velde, Christopher Enny, Aleksandra Rizo, Burhan Ferhanoglu

Blood (2015) 126 (16): 1893–1901.

https://doi.org/10.1182/blood-2015-03-632430

Published: 2015

Includes: Supplemental data

Journal Articles

Non-Intensive but Constant and Exhausting Action on the Leukemic Clone Is a Reasonable and Effective Treatment Approach in Adult Acute Lymphoblastic Leukemia: Results of the Russian Acute Lymphoblastic Leukemia (RALL) Study Group

Blood (2014) 124 (21): 3662.

https://doi.org/10.1182/blood.V124.21.3662.3662

Published: 2014

Journal Articles

Conventional 7+3 Consolidation Is Equal in Long-Term Outcome to High Dose ARA-C in Case of the High Total Doses of Different Anthracyclines/Anthracenedione in Induction/Consolidation - the Interim Results of Russian Randomized Multicenter AML-10 Trial

Blood (2014) 124 (21): 3667.

https://doi.org/10.1182/blood.V124.21.3667.3667

Published: 2014

Journal Articles

First Line BR in Chronic Lymphocytic Leukemia Patients: Interim Results of Russian Norma Trial

Blood (2014) 124 (21): 3332.

https://doi.org/10.1182/blood.V124.21.3332.3332

Published: 2014

NARROW

Long-Term Efficacy and Safety (27 months) of the Biosimilar CT-P10 in Patients with Low Tumor Burden Follicular Lymphoma

Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial

Interim Results of Russian Acute Lymphoblastic Leukemia (RALL-2016) Study with Centralized MRD-Monitoring and Randomization for Autologous HSCT with Non-Myeloablative Conditioning in Adult Ph-Negative ALL Patients

Comparison of Efficacy and Safety of Biosimilar CT-P10 to Rituximab in Patients with Previously Untreated Low Tumor Burden Follicular Lymphoma (LTBFL): A Randomized Phase III Study

Ibrutinib + Obinutuzumab Versus Chlorambucil + Obinutuzumab As First-Line Treatment in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL): Results from Phase 3 iLLUMINATE

A Global, Randomized, Placebo-Controlled, Phase 3 Study of Ibrutinib Plus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (RCHOP) in Patients with Previously Untreated Non-Germinal Center B-Cell-like (GCB) Diffuse Large B-Cell Lymphoma (DLBCL)

MRD Status Did Not Correspond to the Relapse Incidence within One Year of Follow-up By Non-Intensive but Non-Interruptive Approach: The First Interim Results of the Russian Prospective Multicenter RALL-2016 Trial for Ph-Negative Adult ALL

Multiple Myeloma in Russia (First Results of the Registration Trial)

Systemic Exposure of Rituximab Increased By Ibrutinib: Pharmacokinetic Results from the Helios Trial

Absence of High-Dose Consolidation Courses and Low Numbers of Allogeneic HSCTs Did Not Affect Overall Optimistic Results in B-Cell Precursor Ph-Negative Adult ALL Patients Treated By Non-Intensive but Non-Interruptive ALL-2009 Protocol: Data of the Russian ALL Study Group

Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL

Non-Intensive but Constant and Exhausting Action on the Leukemic Clone Is a Reasonable and Effective Treatment Approach in Adult Acute Lymphoblastic Leukemia: Results of the Russian Acute Lymphoblastic Leukemia (RALL) Study Group

Conventional 7+3 Consolidation Is Equal in Long-Term Outcome to High Dose ARA-C in Case of the High Total Doses of Different Anthracyclines/Anthracenedione in Induction/Consolidation - the Interim Results of Russian Randomized Multicenter AML-10 Trial

First Line BR in Chronic Lymphocytic Leukemia Patients: Interim Results of Russian Norma Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only